MARKET

ARQT

ARQT

Arcutis Biotherapeutics, Inc.
NASDAQ
27.32
+1.25
+4.79%
After Hours: 27.30 -0.02 -0.07% 19:20 02/06 EST
OPEN
26.50
PREV CLOSE
26.07
HIGH
27.50
LOW
26.41
VOLUME
1.36M
TURNOVER
--
52 WEEK HIGH
31.77
52 WEEK LOW
11.13
MARKET CAP
3.35B
P/E (TTM)
-77.0880
1D
5D
1M
3M
1Y
5Y
1D
Arcutis ZORYVE Infant Data Adds New Dimension To Atopic Dermatitis Thesis
Simply Wall St · 1d ago
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit
The Motley Fool · 2d ago
Arcutis Biotherapeutics Grants 94,000 Restricted Stock Units to New Employees
Reuters · 2d ago
ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 2d ago
Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 2d ago
Director Howard G. Welgus Reports Sale of Arcutis Biotherapeutics Common Shares
Reuters · 3d ago
Will Positive Infant Phase 2 ZORYVE Data Expand Arcutis Biotherapeutics' (ARQT) Atopic Dermatitis Narrative?
Simply Wall St · 5d ago
Arcutis Buy Rating: Zoryve’s Strengthened Pediatric Data and Undervalued Long-Term Revenue Potential
TipRanks · 5d ago
More
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

Webull offers Arcutis Biotherapeutics Inc stock information, including NASDAQ: ARQT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARQT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARQT stock methods without spending real money on the virtual paper trading platform.